« Back to Farmacia Journal 5/2014

BETADINE® IN CHEMICAL PLEURODESIS

CLAUDIU NISTOR^1*, AURELIAN-EMIL RANETTI², ADRIAN CIUCHE¹, DANIEL PANTILE¹, LAURA–MARIANA CONSTANTIN³, ROXANA BRÎNCOVEANU⁴

Download Full Article PDF

Malignant pleural effusions (MPEs) represent a common complication which can occur in any neoplastic disease. Between October 2012 and December 2013 we performed a prospective study aimed to establish the adequate treatment for malignant pleural effusions. 85 patients were included in this study, diagnosed and treated in the Thoracic Surgery Department of the Central Military Emergency University Hospital. 46 patients underwent chemical pleurodesis with betadine® (through thoracoscopic surgery – 30 patients – or through a chest drainage tube – 16 patients), while for 39 patients talcum powder was chosen as the agent for pleurodesis (through thoracoscopic surgery – 28 patients – or through a chest drainage tube – 11 patients with major surgical risk). The most frequent cancers with secondary MPEs were lung cancers (50 patients). The efficiency of the two methods was the same. The most used chemical pleurodesis procedure was the thoracoscopic surgery (58 patients). The most used agent for pleurodesis was Betadine® (30 patients). Chemical pleurodesis with Betadine® is a safe procedure, which can be used intraoperative (thoracoscopic surgery) or through a chest drainage tube (for patients with major surgical risk). Chemical pleurodesis with Betadine® plays an important role in addressing MPEs because of its high therapeutic efficiency and lower complications rate when compared to other agents (talcum powder).